Full Name
Dr. Olivier Hermine MD, PhD
Job Title
Head of the Hematological Department
Company/Affiliation
Imagine Institute
Speaker Bio
Olivier Hermine, MD, PhD, is a Professor of Hematology at the University of Paris Cité and Head of the Clinical Department of Hematology at Hôpital Necker–Enfants Malades. He is the founder and coordinator of the National Reference Center on Mastocytosis.
He also leads a research group on the pathophysiology and treatment of hematological disorders at the Imagine Institute and is the founder and coordinator of the Laboratories of Excellence on Red Cells in France, as well as coordinator of a nationally funded translational and clinical research program on sickle cell disease.
He teaches both basic and clinical hematology at multiple levels, from undergraduate through MD and PhD training at the University of Paris Cité.
Dr. Hermine is a board member of the Imagine Institute, where he is in charge of the Clinical and Translational Research Committee, and is co-founder and Scientific Director of the École Polytechnique–HEC Bioentrepreneur Program.
He is a current member of the American Society of Hematology and an active member of the Red Cell Committee. He is also a board member of the EBMT Lymphoma Working Group and Chairman of the Mantle Cell Subcommittee of the European Mantle Cell Network. Additionally, he is a member of the scientific and administrative committee and coordinator of the Mantle Cell Group of LYSA (French Lymphoma Study Association), a member of the International Retrovirology Association (IRVA), and co-founder and Scientific Director of the French CELAC Group on Intestinal Lymphoma. He is also an active participant in the European Competence Network on Mastocytosis (ECNM).
Dr. Hermine has been elected to the French National Academy of Sciences, the French National Academy of Pharmacy, the Royal Academy of Medicine of Belgium, and Academia Europaea in the Human and Veterinary Medicine section. He contributed to the WHO/ICC classification of lymphoproliferative disorders.
He is the co-author of more than 1,000 peer-reviewed publications in international scientific journals and co-founder of two biotechnology companies: Inatherys (focused on monoclonal antibodies targeting the transferrin receptor in hematologic malignancies) and AB Science (focused on kinase inhibitors).
Overall, his research aims to understand the mechanisms underlying hematologic malignancies and benign hematologic disorders in humans and animals, with the goal of improving patient care and developing targeted and immune-based therapies.
He also leads a research group on the pathophysiology and treatment of hematological disorders at the Imagine Institute and is the founder and coordinator of the Laboratories of Excellence on Red Cells in France, as well as coordinator of a nationally funded translational and clinical research program on sickle cell disease.
He teaches both basic and clinical hematology at multiple levels, from undergraduate through MD and PhD training at the University of Paris Cité.
Dr. Hermine is a board member of the Imagine Institute, where he is in charge of the Clinical and Translational Research Committee, and is co-founder and Scientific Director of the École Polytechnique–HEC Bioentrepreneur Program.
He is a current member of the American Society of Hematology and an active member of the Red Cell Committee. He is also a board member of the EBMT Lymphoma Working Group and Chairman of the Mantle Cell Subcommittee of the European Mantle Cell Network. Additionally, he is a member of the scientific and administrative committee and coordinator of the Mantle Cell Group of LYSA (French Lymphoma Study Association), a member of the International Retrovirology Association (IRVA), and co-founder and Scientific Director of the French CELAC Group on Intestinal Lymphoma. He is also an active participant in the European Competence Network on Mastocytosis (ECNM).
Dr. Hermine has been elected to the French National Academy of Sciences, the French National Academy of Pharmacy, the Royal Academy of Medicine of Belgium, and Academia Europaea in the Human and Veterinary Medicine section. He contributed to the WHO/ICC classification of lymphoproliferative disorders.
He is the co-author of more than 1,000 peer-reviewed publications in international scientific journals and co-founder of two biotechnology companies: Inatherys (focused on monoclonal antibodies targeting the transferrin receptor in hematologic malignancies) and AB Science (focused on kinase inhibitors).
Overall, his research aims to understand the mechanisms underlying hematologic malignancies and benign hematologic disorders in humans and animals, with the goal of improving patient care and developing targeted and immune-based therapies.
Speaking At
